Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory

International Journal of Laboratory Hematology

Volumn 37, Issue S1, 2015, Pages 46-51

  Gosselin, R C ^a   Adcock, D M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Anticoagulants; Laboratory practice; NOAC

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN ETEXILATE; REAGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN;

ANTICOAGULATION; BLOOD CLOTTING TEST; CALIBRATION; CLINICAL LABORATORY; DRUG MONITORING; DRUG SAFETY; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; REVIEW; BLOOD CLOTTING; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PROCEDURES; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; DABIGATRAN; DRUG MONITORING; FACTOR XA INHIBITORS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS;

EID: 84929347366     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12350     Document Type: Review

References (13)

1. Gosselin R, Hawes E, Moll S, et al. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses. Am J Clin Pathol 2014;141:262-7.
2. Gosselin RC, Adcock DM, Taylor M, et al. Comparison of anti-Xa and dilute Russell Viper Venom Time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 2014;138:1680-4.
3. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11:756-60.
4. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427-9.
5. Gosselin RC, Adcock A, Hawes EM, et al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost 2015;113:77-84.
6. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamics study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-502.
7. Huisman MY, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47.
8. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamics study based on peak and trough plasma levels. Thromb Haemost 2014;111:1133-40.
9. Samama MM, Mendell J, Guinet C, et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2011;129:e77-82.
10. Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor endoxaban. Am J Clin Pathol 2015;143:241-7.
11. Adcock DM, Gosselin R, Kitchen S, et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-9.
12. Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013;110:283-94.
13. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32:183-7.